Financials in USD. Standardized financial statements.
A compact view of how Taysha Gene Therapies, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $9.77M | $8.33M | $15.45M | $2.50M | $0 | $0 | $0 |
| Revenue Growth? | +17.3% | -46.1% | +517.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $2.49M | $0 | $9,000 | $0 |
| Gross Profit? | $9.77M | $8.33M | $15.45M | $14,999 | $0 | -$9,000 | $0 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +0.6% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $120.27M | $99.79M | $87.89M | $126.04M | $173.27M | $42.99M | $1.11M |
| Operating Income? | -$110.50M | -$91.46M | -$72.44M | -$126.03M | -$173.27M | -$43.00M | -$1.11M |
| EBITDA? | -$107.79M | -$87.95M | -$105.20M | -$159.73M | -$172.60M | -$59.97M | $0 |
| Income Before Tax | -$109.00M | -$89.30M | -$111.57M | -$166.01M | -$174.52M | -$60.01M | -$1.11M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$109.00M | -$89.30M | -$111.57M | -$166.01M | -$174.52M | -$43.00M | -$1.11M |
| EPS? | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-3.40 | $-0.03 |
| Diluted EPS? | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-3.40 | $-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality